ABSTRACT
Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral genome in wastewater has proven to be useful for tracking the trends of virus prevalence within the community. The surveillance also provides precise and early detection of any new and circulating variants, which aids in response to viral outbreaks. Site-specific monitoring of SARS-CoV-2 variants provides valuable information on the prevalence of new or emerging variants in the community. We sequenced the genomic RNA of viruses present in the wastewater samples and analyzed for the prevalence of SARS-CoV-2 variants as well as other respiratory viruses for a period of one year to account for seasonal variations. The samples were collected from the Reno-Sparks metropolitan area on a weekly basis between November 2021 to November 2022. Samples were analyzed to detect the levels of SARS-CoV-2 genomic copies and variants identification. This study confirmed that wastewater monitoring of SARS-CoV-2 variants can be used for community surveillance and early detection of circulating variants and supports wastewater-based epidemiology (WBE) as a complement to clinical respiratory virus testing as a healthcare response effort. Our study showed the persistence of the SARS-CoV-2 virus throughout the year compared to a seasonal presence of other respiratory viruses, implicating SARS-CoV-2’s broad genetic diversity and strength to persist and infect susceptible hosts. Through secondary analysis, we further identified antimicrobial resistance (AMR) genes in the same wastewater samples and found WBE to be a feasible tool for community AMR detection and monitoring.
HIGHLIGHTS/KEY FINDINGS
WBE better represents regional virus prevalence under declining testing and clinical reporting rates.
SARS-CoV-2 virus was present throughout the year compared to a seasonal prevalence of other respiratory viral pathogens.
SARS-CoV-2 variant monitoring via WBE can provide insights into regionally co-circulating respiratory viruses, causing flu-like symptoms.
WBE-AMR gene monitoring is feasible and provides valuable insight into regional AMRs.
Our workflow enables the estimation of the relative proportion of different variants in any pooled samples.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Coronavirus Aid, Relief, and Economic Security (CARES) Act from the US Treasury.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
DISCLOSURE None.
FUNDING The Coronavirus Aid, Relief, and Economic Security (CARES) Act from the US Treasury.
DATA SHARING The data for the study are submitted as BioSamples to NCBI Genbank under BioProject ID PRJNA772783, available at https://www.ncbi.nlm.nih.gov/bioproject/772783.
CONFLICTS OF INTEREST None.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
